Polaryx Therapeutics, Inc.
- PLYX ยท Nasdaq
- Pharmaceutical Preparations
- Paramus, NJ
- 11 employees
- CIK 0002075320
Updated from SEC filings through
Top things to know
Executives
-
Alex Keun Mo Yang Chief Executive Officer Form 4, May 28, 2026 -
G. Michael Landis Chief Financial Officer Form 4, February 20, 2026 -
Lisa L. Bollinger, M.D. Chief Medical Officer 10-K, March 24, 2026 - Andrew John O. Chief Investment Officer Form 3, January 29, 2026
Polaryx Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Paramus, NJ. It trades as PLYX on Nasdaq. It reported about 11 employees.
Five-year financials
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | Not on file | Not on file |
| Operating income | -$7.8M 10-K, 2026-03-24 | -$4.4M 10-K, 2026-03-24 |
| SG&A | $1.6M 10-K, 2026-03-24 | $1.5M 10-K, 2026-03-24 |
| Net income | -$9.0M 10-K, 2026-03-24 | -$30.4M 10-K, 2026-03-24 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer | Form 4, May 28, 2026 |
| | Chief Financial Officer | Form 4, February 20, 2026 |
| | Chief Medical Officer | 10-K, March 24, 2026 |
| Andrew John O. | Chief Investment Officer | Form 3, January 29, 2026 |
| Francis A. Braun III | Director | 10-K, March 24, 2026 |
| Mitchel Berger, M.D. | Director | 10-K, March 24, 2026 |
What Polaryx Therapeutics, Inc. does
PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed, reformulated drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the second half of 2026.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 49.8 million (as of October 31, 2026) | 10-Q, November 12, 2026 |
|---|---|---|
| Public float | $0 (as of June 30, 2025) | 10-K, March 24, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 12, 2026 |
| Latest proxy statement | Meeting September 10, 2026 (filed July 28, 2026) | DEF 14A, July 28, 2026 |
| Auditor | Grant Thornton LLP (Edison, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| May 27, 2026 | Alex Keun Mo Yang Chief Executive Officer | Buy | 88,453 | $360K | Form 4, May 28, 2026 |
| May 27, 2026 | Partners Healthcare Ltd Mstone Director | Buy | 88,453 | $360K | Form 4, May 28, 2026 |
| February 18, 2026 | G. Michael Landis Chief Financial Officer | Buy | 2,867 | $8K | Form 4, February 20, 2026 |
Recent 8-K events
- 8-K filed 2026-09-14
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-09-01
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-07-21
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-17
- Item 5.08 Item 5.08
- Item 8.01 Other events
- 8-K filed 2026-05-28
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Polaryx Therapeutics, Inc.
- What does Polaryx Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed, reformulated drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the second half of 2026."
- How many employees does Polaryx Therapeutics, Inc. have?
- About 11 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of Polaryx Therapeutics, Inc.?
- G. Michael Landis, Chief Financial Officer, as named in a 4 filed February 20, 2026.
- Where is Polaryx Therapeutics, Inc. headquartered?
- Paramus, NJ.
- What is Polaryx Therapeutics, Inc.'s stock ticker?
- PLYX on Nasdaq.
- What industry is Polaryx Therapeutics, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Polaryx Therapeutics, Inc.'s website?
- polaryx.com. Investor relations: https://investors.polaryx.com.
- When does Polaryx Therapeutics, Inc. report earnings next?
- February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Polaryx Therapeutics, Inc. a public company?
- Yes. Polaryx Therapeutics, Inc. files with the SEC under CIK 0002075320 and trades as PLYX.
- Who audits Polaryx Therapeutics, Inc.?
- Grant Thornton LLP, Edison, New Jersey, as named in its latest annual report (10-K).
- How many shares of Polaryx Therapeutics, Inc. are outstanding?
- 49.8 million shares as of October 31, 2026, from its 10-Q filed November 12, 2026.
- What is Polaryx Therapeutics, Inc.'s public float?
- $0 as of June 30, 2025, as reported on the cover of its 10-K filed March 24, 2026.
- How many business segments does Polaryx Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
- When is Polaryx Therapeutics, Inc.'s annual shareholder meeting?
- September 10, 2026, per its proxy statement (DEF 14A) filed July 28, 2026.
- Have Polaryx Therapeutics, Inc. insiders traded stock recently?
- Since February 18, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $728K on Forms 4 and 5. The most recent: Alex Keun Mo Yang (Chief Executive Officer) bought 88,453 shares on May 27, 2026.